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Metformin in Health Issues and 
Reproductive System
Elham Pourmatroud
Abstract
Metformin is one of oldest drug in reproductive medicine era; but most of times 
it is equal to polycystic ovary (PCO) syndrome especially obese patients. If it is 
still valuable or not, could have another health benefit or new fertility roles, and 
could be effective as well in male reproductive system will be discussed. According 
to increased rate of metabolic disorders and cardiovascular problems and cancers, 
there are several investigations on this old used drug. Those studies had been 
magnified its role as “the aspirin of current century,” which might have a promising 
role in longevity of the life. So, the chapter will be interesting.
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1. Introduction
Metformin is a component of many herbal therapeutic substances, which has 
been known since 1500 BCE in Egyptian medicine [1]. In Europe, a herbal remedy 
was used for ameliorating polyuria and polydipsia; from the Middle Ages, its name 
was Galega officinalis (or the French lilac) [2]. However, just in the early 1900s, the 
effective element “guanidine” was extracted [3].
Everybody knows that the incidence and prevalence of diabetes mellitus (DM) 
is increasing constantly. Diabetes is one of the most common noncommunicable 
diseases and is considered as one of the top five universal causes of precocious death 
in both developed and non-developed countries. So the immense numbers of stud-
ies about metformin, which is the most prevalent and popular remedy for it, could 
be predictable. As a result, it is no wonder that there is a scanty paper about other 
worthful aspects of metformin.
Metformin has been called “the aspirin of the twenty-first century [4].” This 
old-fashioned drug was famous only as antidiabetic drug until recent years. 
So, what makes this drug so hear saying and impressive for life longevity [5], 
prevention from cancers [6] and useful in patients with chronic kidney disease, 
congestive heart failure or chronic liver disease [7]. At the present time, evidence 
suggests that metformin’s wide-spectrum advantages are mediated by at least two 
relevant pathways: first, by inhibition of intracellular metabolic activity of mito-
chondria and second, the cellular nutrition-sensing system mediated by mTOR 
[4]. (“The mammalian target of rapamycin” is one kind of the kinase family that 
mediates metabolism and cell growth as a reaction to growth factors, nutrients, 
and stress [8].)
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In this chapter we are going to talk about three different fields of metformin 
action in detail.
2. Health issues
In accordance with aging, there are some significant changes in the body and 
elevation in prevalence of some specific disease and abnormality [9].
• Endocrine system: type 2 diabetes, thyroid disease, osteoporosis, and ortho-
static hypotension
• Cardiovascular: hearth failure, hypertension, and CVD
• Neurological: delirium, cognitive impairment, and dementia
• Optical: macular degeneration, cataract, and presbyopia
• Muscular: impaired mobility, muscular strength, and sarcopenia
• Auditory: presbycusis and conductive hearing loss
• Skeletal: osteoporosis, kyphosis, and scoliosis
• Gastrointestinal: dysphagia, constipation, and malabsorption
• Renal: chronic kidney disease
• Immune: increased risk of infections
• Dermal: dryness and lower elasticity and pressure ulcer
The life span has been regulated by pharmacologic, genetic, and dietary inter-
ferences in several sample systems. The most considerable mechanism in aging 
phenomenon is DNA damage; the endogenous, potent factors are reactive oxygen 
species (ROS), alkylation, and hydrolysis [10]. Thus, most studies in this subject are 
focusing on it.
Through the metformin role in aging, it leads to decreased insulin levels, inhi-
bition of mTOR, decreased IGF-1 signaling, endogenous production of reactive 
oxygen species, inhibition of mitochondrial complex 1, activation of AMP-activated 
protein kinase (AMPK), and reduction in DNA damage.
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) is a pro-
tein complex that governs transcription of DNA. Metformin inhibits NF-kB, a key 
point in inflammatory process [11]. Also, by lowering the reactive oxygen species 
and improving the endothelial function [12], reduction in coronary heart diseases 
and cerebrovascular accidents after metformin administration could be expected. 
With those mechanisms, the effectiveness in blood hemostasis is considerable; 
reduction in systemic production of the tissue type plasminogen activator, Von 
Willibrand factor, and plasminogen activator inhibitor [13], furthermore modula-
tion the fibrin threads formation in both diabetic and non-diabetic patients [14].
According to one recent meta-analysis, metformin is operative in reducing 
body weight of simple obesity (in nondiabetic, non-polycystic ovary syndrome 
(PCOS) patients), by reducing the absorption of glucose in the intestine, decreasing 
3Metformin in Health Issues and Reproductive System
DOI: http://dx.doi.org/10.5772/intechopen.90465
production of glucose in the liver, and ameliorating insulin sensitivity via increasing 
muscle glucose uptake and use [15].
The role of metformin in the nervous system is proposed excitingly. Alzheimer 
is a disease with an advanced insulin resistance of the brain cell which leads to 
formation of the amyloid cells [16]. Undesirable oxidative damages and inactiva-
tion of AMPK pathway [17] and making delay in mitochondria programmed cell 
death could be mediated by metformin [18]. Besides Alzheimer, other neurological 
diseases like Parkinson and amyotrophic lateral sclerosis have the same mechanism.
As a result of conversion in the insulin resistance, depletion in intestinal absorp-
tion of carbohydrate and leptin secretion, and enhancing effects of glucagon-like 
peptide-1 on fat cells, metformin could be applied for weight reduction [19].
Additionally, prescription of metformin with antiretroviral agents (especially 
in HIV treatment) has been showed a reduction in their side effects like the risk of 
insulin insensitivity, weight obtain, dyslipidemia, and hyperglycemia [20].
In cancerous issue, there are several studies that depict the effectiveness of 
metformin.
One meta-analysis has concluded that metformin plays a role in the decline of 
liver cancer risk in type 2 diabetes patients [21]. The anti-tumorigenic sequel of 
metformin in pancreatic cancer [22], colorectal cancer [23], prostate cancer [24], 
and lung cancer [25] and its role in lowering the risk of cancer-related mortality 
have been proposed. From another aspect, in colorectal cancers’ cell, metformin 
inhibits an essential energy source: adenosine A1 receptor (ADORA1) [26].
As we mentioned before, lowering the insulin levels by metformin ends in 
reduction in the levels of P13K pathway. (The PI3K/AKT/mTOR pathway is an 
intracellular signaling pathway with significant regulating function in all of the 
cellular stages: quiescence, proliferation, cancer, and longevity.) Moreover metfor-
min by forcing effect on AMPK lowers the ATP ratio in cells causing switch-off of 
cell growth and proliferation in breast cell [27]. In breast cancer, metformin has an 
inhibitory effect at early stages of cell differentiation [28]; indeed, the antineoplas-
tic effects need higher-dose consumption and more clinical evidences [29]. With 
those outstanding impressive mechanisms of metformin, a smaller size and slower 
progression of thyroid cancer [30] and advantageous effect on endometrium cancer 
including progesterone-resistant cancer cells [31] have been pointed.
Metformin could have an adjuvant task in treating cervical cancer, particularly 
in types with liver kinase B1 (LKB1) positive (a gen with tumor suppression effi-
cacy) [32]. Eventually, there is an update study about metformin’s anti-metastatic 
effects on aggressive malignancies like melanomas [33].
From another aspect, metformin decreases the frequency of preeclampsia, by 
reduction in the production of anti-angiogenic factors (soluble vascular endothelial 
growth factor receptor-1 and soluble endoglin) and the modification in endothelial 
dysfunction [34].
It must be highlighted that all of mentioned witnesses are extra glycemic effects 
of metformin in health jeopardies in nondiabetic patients.
3. Fertility issues
Metformin as a hydrophilic biguanide is present in many tissues like the hypo-
thalamus, pituitary, and gonads moreover than famous places (liver, pancreas, and 
adipose tissues). It could be accumulating in specific tissues more than plasma level 
by particular transportation system, in which one of those places is the reproductive 
system [35]. Metformin activates the cytoplasmic protein kinase, which is a well-
known enzyme: AMPK.
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AMPK is a sensitive and important sensor of cellular energy homeostasis.
Hypothalamic neurons secrete gonadotropin-releasing hormone (GnRH) that 
stimulates follicle-stimulating hormone (FSH) and luteinizing hormone (LH) 
production from the pituitary gland. GnRH function in the brain has an AMPK-
dependent pathway. Metformin as an AMPK activator decreases the amplitude of 
FSH and LH secretion.
3.1 Male reproductive system
Spermatogenesis is under noticeable hormonal regulation, especially by pitu-
itary hormones (FSH and LH). LH stimulates the Leydig cells (LCs) to secrete 
testosterone and dihydrotestosterone, although FSH arouses Sertoli cells (SCs) 
of seminiferous tubules to maintain the cycle of spermatogenesis and inhibin 
secretion. Respectively, testosterone and inhibin secretion from the testis cause a 
negative feedback with inhibitory effects on FSH and LH. This regular system is 
necessary for normal spermatogenesis [36].
During spermatogenesis, the evolution process of germ cells into mature and 
motile spermatozoa needs specific nutrient sources which are obtained mainly from 
sugars (particularly glucose and fructose) and other metabolites such as lactate and 
citrate. Those metabolites are the most principal fuels for ATP production in germ 
cells and spermatozoa [37].
Moreover, production of lactate by glycolytic pathway in the SCs [38] and 
secretion into intratubular fluid is a necessary step for germ cell spermatogenesis. 
This is another energy-making way, important for motility enhancement. This 
process is controlled directly by glucose metabolism [39]. After primary spermato-
zoa production, they will store in the epididymis. Here final maturation occurs by 
advancement in motility function and fertilization capacity. All of those processes 
demand high energy and depend on glucose transporter (GLUT) proteins for 
carrying glucose through sperm’s lipidic membrane inside the sperm cell [40]. In 
effect, regular and correct male fertility through this long journey is closely related 
to glucose metabolism.
Metformin’s effect on human male reproductive function still is obscure. 
Extensively, current data are extracted from normal animal model studies, particu-
larly rodents and diabetic men.
In healthy male animals, exposure to metformin displays adverse reproductive 
outcomes like:
1. Decrease in testosterone production [41].
2. Reduction in seminiferous tubules diameter and testis size.
3. Reduction in Sertoli cell numbers [42].
4. Decrease in sperm quality parameters [43].
In diabetic men, according to hyperglycemic state and excessive ROS produc-
tion, metformin improves antioxidant environment of the testis and enhances 
steroidogenesis. This favorable amelioration in the testis leads to increase in con-
centration of motile sperm and normal morphological sperm [44]. Furthermore, 
metformin increases endothelial nitric oxide synthase phosphorylation [45] and 
the contractility in the corpora cavernosa [46], so sexual disorders like retrograde 
ejaculation or erectile dysfunction could be mended.
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Recently, evidences of metformin efficacy in nondiabetic men are increasing. 
As remarked above, lactate synthesis by SCs is a crucial step in testicular metabolic 
cycle, which produces more desirable energy substrate for springing up germ cells 
and has a prominent anti-apoptotic effect [47]. Also, some studies showed that 
metformin plays a role as a suppressor of complex I of the mitochondrial electron 
transport chain that directly decreases oxidative metabolism and accordingly 
increases anaerobic respiration and lactate secretion [48].
Surprisingly, adding metformin in cryopreservation media during sperm 
freezing practice (for fertility preservation) reduces sperm permanent damage and 
improves the rate of success in fertilization process and decreases the number of 
abnormal zygotes after in vitro fertilization [49].
3.2 Female reproductive system
As it is well-known, metformin has a crucial role in PCOS pathogenesis amelio-
ration and not surprising the large number of studies about its efficacy and wide-
spread utilization. But, when we are looking for its usage in non-PCOS infertile or 
subfertile woman, unexpectedly, there is scanty study about it.
Insulin resistance could have significant negative role in various conditions such 
as stress [50], aging [51], obesity [52], depression [53], and inactive lifestyle [54]. 
Infertile women often have one of those conditions. Moreover, ovarian dysfunction 
induces “stress response mechanism” owing to abnormal cortisol secretion and 
increased level of catecholamines [55]. Besides that, by enhancing in insulin-like 
growth factor-binding protein-1 and glycodelin level, uterine vascularity and blood 
flow could be increased [56].
Those beneficial effects had been demonstrated in a study on about 200 patients 
(non-PCOS) with repeated IVF failure. In this study in a period of 8–12 weeks, 
low-dose (500 mg/day) metformin administration before IVF cycle significantly 
increases the pregnancy rate by improving in oocyte quality and endometrium, 
receptivity [57].
In another bovine study, it was shown that IGF-1 has a dual positive role in 
follicle regulation which increases FSH effectiveness as an autocrine regulator of 
granulosa cell growth that could illustrate metformin worth in infertility treatment 
procedures [58]. Moreover, in vitro experiment studies show that metformin could 
decrease the progesterone [59] and estradiol [60] secretion from granulosa cells and 
androstenedione [61] from theca cells.
4. Conclusion
As we reviewed in this chapter, metformin did not equal to NIDDM and PCOS, 
anymore. In all of the mentioned fields, researches are increasing more and more.
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